UCL's Freeline Therapeutics has priced its shares at $18 to raise nearly $159m through an IPO on the Nasdaq Global Select Market.

Freeline Therapeutics, a UK-based gene therapy developer based on University College London (UCL) research, has priced its shares at $18 and will raise almost $159m when it goes public today. The company issued more than 8.8 million American Depositary Shares (ADSs), representing the same number of ordinary shares. Commercialisation firm Syncona invested $24.3m in the…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.